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Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported
results from either private institutional data or publicly available datasets. However, current public
datasets are limited in terms of: a) number of subjects, b) lack of consistent acquisition protocol,
c) data quality, or d) accompanying clinical, demographic, and molecular information. Toward
alleviating these limitations, we contribute the “University of Pennsylvania Glioblastoma Imaging,
Genomics, and Radiomics” (UPenn-GBM) dataset, which describes the currently largest publicly
available comprehensive collection of 630 patients diagnosed with de novo glioblastoma. The UPennGBM dataset includes (a) advanced multi-parametric magnetic resonance imaging scans acquired
during routine clinical practice, at the University of Pennsylvania Health System, (b) accompanying
clinical, demographic, and molecular information, (d) perfusion and diffusion derivative volumes,
(e) computationally-derived and manually-revised expert annotations of tumor sub-regions, as well as
(f) quantitative imaging (also known as radiomic) features corresponding to each of these regions. This
collection describes our contribution towards repeatable, reproducible, and comparative quantitative
studies leading to new predictive, prognostic, and diagnostic assessments.

Background & Summary

Glioblastoma (GBM) is the most common, complex, and aggressive adult primary tumor of the central nervous
system (CNS). Although the currently applicable standard-of-care treatment options (i.e., surgery, radiotherapy, chemotherapy) have expanded during the last 20 years, there is no substantial improvement in patient
overall survival (OS). Despite various attempts targeting diagnostic and therapeutic advances, the reported
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Fig. 1 Visual summary of the “University of Pennsylvania Glioblastoma Advanced Imaging, Clinical,
Genomics, and Radiomics” (UPenn-GBM) data collection.

prognostication of GBM patients still remains at a median OS rate of 16–20 months following standard of care
therapy and 5-year survival rate of 10%1. A major obstacle in treating GBM and extending patient OS relates,
in part, to the underlying spatio-temporal heterogeneity of its molecular and micro-environmental landscape
that are also reflected at the phenotypic level2–14. Numerous translational, computational, and clinical research
studies have been conducted and reported results from either private institutional data or publicly available
datasets15–30. However, current public datasets are limited in terms of: (a) the number of included subjects, (b)
lack of consistent acquisition protocol, (c) variable quality of data, or (d) accompanying clinical, demographic,
and molecular information.
To address these limitations, and facilitate further studies towards understanding mechanisms of this disease,
we introduce the “University of Pennsylvania Glioblastoma Imaging, Genomics, and Radiomics” (UPenn-GBM)
dataset, which describes the currently largest publicly available comprehensive dataset of 630 patients diagnosed
with de novo GBM (Fig. 1). The complete UPenn-GBM collection is made freely available to browse, download,
and use via The Cancer Imaging Archive (TCIA)31, as outlined in the Creative Commons Attribution Unported
(CC BY) License.
The UPenn-GBM collection specifically includes a) advanced multi-parametric magnetic resonance imaging
(mpMRI) scans acquired consistently at the University of Pennsylvania Health System (UPHS) during routine clinical radiologic exams, at the pre-operative baseline time-point for 611 patients, and at the follow up
time-point prior to second surgery for a subset of them, b) accompanying clinical and demographic data, inclusive of age, gender, resection status, Karnofsky performance score (KPS) prior to treatment, survival information from first surgical operation, and a predicted pseudoprogression index, c) molecular status for Isocitrate
dehydrogenase 1 (IDH1) mutations based on next generation sequencing (NGS) and/or immunohistochemical
staining for IDH1-R132H, and methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter based on pyrosequencing32. In addition to these clinically acquired data, the UPenn-GBM dataset further
includes: d) pre-processed scans according to a standardized protocol15–18,33 (inclusive of co-registration of all
mpMRI scans in a common anatomical atlas, resampling to an isotropic resolution of 1mm3, and skull-stripping)
e) extracted perfusion and diffusion derivative volumetric scans, f) computationally-derived and manually
revised expert annotations of tumor sub-region boundaries, as well as g) quantitative imaging (also known as
radiomic) features34–36, corresponding to each of these regions.
The contribution on the UPenn-GBM dataset is two-fold: (a) its potential for re-use towards repeatable,
reproducible, and comparative quantitative translational, computational, and clinical research studies leading
to new predictive, prognostic, and diagnostic assessments, enabled by direct utilization through TCIA37, and
(b) benefiting both clinical and computational imaging researchers targeting the development and evaluation
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Demographics
Gender

Age (years)

Resection Status

Imaging

Scan Time-point

Value

Number

%

Female

252

40.0%

Male

378

60.0%

18–29

14

2.2%

30–49

69

11.0%

50–69

367

58.3%

70+

180

28.6%

Gross Total

362

59.2%

Partial

211

34.5%

Unknown

38

6.2%

Structural scans

671

100.0%

DTI

592

88.2%

DSC

534

79.6%

Pre-operative

611

91.1%

Follow up

60

8.9%

Methylated

140

22.9%

177

29.0%

Unknown

294

48.1%

Mutated

16

2.6%

Wildtype

499

81.7%

NOS/NEC

96

15.7%

MGMT methylation status Unmethylated

IDH

Table 1. Demographics of the UPenn-GBM data collection.

of quantitative algorithms for segmentation and downstream radiomic analyses associated with clinically
relevant goals. Future planned extensions of this dataset will support more comprehensive radiogenomic
studies, by incorporating most clinically-relevant molecular markers reported in the literature, as well as
radio-patho-genomic research38 aiming to find phenotypic signatures of GBM molecular characteristics.

Methods

In favor of transparency, in this section we provide a detailed description of all the procedures followed to produce the data of the UPenn-GBM collection, including all descriptions of the experimental design, data acquisition assays, and any computational processing (e.g., curation, brain extraction, tumor segmentation, radiomic
feature extraction) towards enabling reproducible research.

Data. The study population was identified on the basis of retrospective review of the electronic medical
records of patients diagnosed with GBM at the UPHS from 2006 to 2018. 630 patients were included in the
UPenn-GBM collection, 611 of which were selected according to the inclusion criteria of: (i) age ≥18 years old,
and (ii) preoperative scans comprising baseline mpMRI at time of diagnosis, comprising the four structural MRI
scans, i.e., native T1-weighted (T1), post-contrast T1 (T1-Gd), native T2-weighted (T2), and T2 fluid attenuated inversion recovery (T2-FLAIR) scans. Diffusion tensor imaging (DTI), and dynamic susceptibility contrast
(DSC) MRI scans were also acquired and provided for most cases. In addition to the 611 baseline pre-operative
scans, the UPenn-GBM collection includes 60 follow-up scans from patients who have undergone a second resection due to progressive radiographic changes. Notably 19 of these 60 cases had available data only the follow
time-point. Summary demographics can be found in Table 1. A summary of the scanner manufacturer, scanner
models, and acquisition settings used to capture each of the cases included in the UPenn-GBM data collection
described here can be found and downloaded from the TCIA repository37.
Patients included in our study were treated according to standard of care, which included maximal safe
resection, radiotherapy, and concomitant and adjuvant chemotherapy with Temolozolomide (TMZ). Collection,
analysis, and release of the UPenn-GBM data has happened in compliance with all relevant ethical regulations.
The protocol was approved by the Institutional Review Board at the UPHS, and informed consent was obtained
from all participants.
Clinical data. Clinico-pathologic information including age, sex, histologic diagnosis, and molecular data, if
available, were obtained directly from the corresponding patient medical records. The age range of the included
population was 18–89. The ratio of male:female was equal to 60:40. The resection status of the 611 patients with
available pre-operative baseline scans was partitioned in the three categorical entries of i) Gross Total Resection
(GTR, n = 362), ii) Partial Resection (PR, n = 211), and iii) Not Available (NA, n = 38), representing excision of
≥90%, <90%, and unknown proportion of the tumor, respectively. The Karnofsky performance score (KPS) prior
to treatment was identified for 75 of the 611 baseline pre-operative scans. Overall survival data is provided for 452
patients, and additional data related to patient prognosis include IDH1 status and MGMT promoter methylation
status (Table 1). All these are downloadable from TCIA37.
Clinico-pathologic information for the follow up cases include a pathological assessment score, in the range
of 1–6, which indicates the degree of tumor progression and treatment effects, following expert evaluation of the
related tissue sections (1 = <10%, 2 = 10%–25%, 3 = 25%–50%, 4 = 50%–75%, 5 = 75%–90%, and 6 = >90%
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malignant features). The exact inclusion criteria for these (as also described in the original study39 obtaining
these scores), comprised 1) initial gross total resection of the tumor core followed by chemo-radiation, 2) new
or increasing enhancement on follow-up MRI, 3) second resection and histopathological tissue evaluation, and
4) acquisition of all modalities (T1, T1-Gd, T2, T2-FLAIR, DSC, and DTI), within 15 days prior to the second
resection.

Molecular characterization. Following the current World Health Organization (WHO) classification of
CNS tumors40, we focus on the mutational status of IDH that was identified for 515 of all the 611 cases with
baseline pre-operative scans. The remaining 96 cases were classified according to “The Consortium to Inform
Molecular and Practical Approaches to CNS Tumor Taxonomy–Not Official WHO (cIMPACT-NOW)” as
IDH-Not-Otherwise-Specified (IDH-NOS)41–48. Note that the role of the cIMPACT-NOW board is to provide
evidence-based scientific updates/refinements beyond the most recent WHO classification of CNS tumors40
towards ensuring the best possible clinical care of patients. Mutations in IDH were found for 16 of the 515 cases
(3.11%), and the remaining ones were classified as wildtype IDH (IDHwt). The mutational status of IDH1 was
determined by Next Generation Sequencing (NGS)32 and/or immunohistochemical staining for IDH1-R132H.
Cases were sequenced on one of the two UPHS clinical solid tumor NGS panels32 or on a research NGS panel.
The original 47-gene clinical panel used the TruSeq Custom Amplicon Cancer Panel kit (Illumina, San Diego,
CA), which targeted hotspot variants. Samples were multiplexed and sequenced on a MiSeq to an average depth
of coverage of 2500 ×. Subsequently, a larger panel was implemented with full gene coverage of 153 genes, using
the Agilent Haloplex design with unique molecular identifiers. Samples were multiplexed and sequenced on a
HiSeq with total deduplicated reads of 6.5 million reads/sample. For both clinical panels, variants were identified
using an in-house data processing bioinformatics pipeline. For the research panel, libraries were prepared using a
custom AmpliSeq panel, Ion AmpliSeq Library Kit 2.0 and templated on an Ion Torrent OneTouch 2 instrument.
Templated libraries are enriched on an Ion OneTouch ES.
The MGMT promoter methylation status by pyrosequencing is available for 317 of the 611 cases, of which 140
had methylation detected and 177 had methylation not detected. To determine the MGMT promoter methylation
status, genomic DNA was extracted from 5-micron tissue sections of formalin-fixed paraffin-embedded (FFPE)
tissue samples containing at least 20% tumor cellularity. Approximately 500–1000 ng total DNA was subjected
to bisulfite conversion using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA). A total of 50–100 ng
bisulfite-treated DNA was carried on for PCR using F-primer (50-GTTTYGGATATGTTGGGATA-30) and
R-primer (50-biotin-ACCCAAACACTCACCAAATC-30), creating a fragment spanning 4 CpG sites in exon
1 of MGMT [(chr10:131,265,529-131,265,537; UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19)
Assembly]. We then conducted the pyrosequencing methylation assay on the PyroMark Q24 (Qiagen) using
the Pyromark MGMT kit to detect the ratio of T:C to determine the level of methylation at the 4 CpG sites. A
mean and median percent methylation across all four CpG sites equal to or greater than 10% was interpreted as
positive. A result with mean and median below 4.5% methylation was interpreted as negative. If both mean and
median were greater than or equal to 4.5%, but at least one was less than 10%, then the result was designated low
positive. If either the mean or median was less than 4.5% but the other was greater than or equal to 4.5%, then
the result was designated indeterminate.
Note that both the IDH mutational status and the MGMT promoter methylation status were originally
derived from the rigorously validated assays and procedures described above. Then the concluding labels were
stored in the patients’ medical records as measurements used routinely for diagnostic and patient treatment
purposes. The “UPenn-GBM” collection makes publicly available these concluding labels, as the underlying raw
clinical data were not available for distribution.
Image Pre-processing. Since the scans included in this study were heterogeneously obtained from different
scanners and acquisition protocols, in addition to providing the scans in their original state (i.e., resolution, orientation), after de-identification and de-facing, they all underwent the same pre-processing protocol to make image
dimensions and voxel sizes uniform across studies and modalities. Details of the original state of the acquired
scans are provided at the TCIA repository37.
All DICOM scans were converted to the Neuroimaging Informatics Technology Initiative (NIfTI)49 file format to facilitate computational analysis, following the well-accepted pre-processing protocol of the International
Brain Tumor Segmentation (BraTS) challenge15–18,33,50. Specifically, all mpMRI volumes were reoriented to the
left-posterior-superior (LPS) coordinate system, and the T1-Gd scan of each patient was rigidly (6 degrees of
freedom) registered and resampled to an isotropic resolution of 1 mm3 based on a common anatomical atlas,
namely SRI51. The remaining scans (i.e., T1, T2, T2-FLAIR) of each patient were then rigidly co-registered to
this resampled T1-Gd scan by first obtaining the rigid transformation matrix to T1-Gd, then combining with
the transformation matrix from T1-Gd to the SRI atlas, and resampling. For all the image registrations we used
the ‘Greedy’ (https://github.com/pyushkevich/greedy, hash: 1a871c1, Last accessed: 27/May/2020) tool52, which
is a central processing unit (CPU)-based C++ implementation of the greedy diffeomorphic registration algorithm53. We further note that use of any non-parametric, non-uniform intensity normalization algorithm54–56 to
correct for intensity non-uniformities caused by the inhomogeneity of the scanner’s magnetic field during image
acquisition, obliterates the T2-FLAIR signal, as it has been previously reported16. Thus, taking this into consideration, we intentionally apply the N4 bias field correction approach55 in all scans temporarily to facilitate an
improved registration of all scans to the common anatomical atlas. Once we obtain the transformation matrices
for all the scans, then we apply these transformations to the non-bias corrected images. A schematic summary of
the preprocessing protocol applied to all the UPenn-GBM data collection can be found at Fig. 2.

Scientific Data |

(2022) 9:453 | https://doi.org/10.1038/s41597-022-01560-7

4

www.nature.com/scientificdata/

www.nature.com/scientificdata

Fig. 2 Schematic representation of the harmonized pre-processing pipeline applied to all the UPenn-GBM
imaging data.

Image De-facing. All co-registered scans were defaced, using the ‘mri_deface’ tool (https://surfer.nmr.mgh.
harvard.edu/fswiki/mri_deface)57. Specifically, the defacing mask is first obtained for the co-registered native
T1-weighted scan, the sequence with which ‘mri_deface’ is designed to work. The defacing masks for all cases
were visually checked and approximately 10% of the masks were manually refined. The defacing mask was then
applied to all co-registered structural MRI scans (i.e., T1-Gd, T1, T2, T2-FLAIR). These defaced data are available
as the “unstripped-structural” scans in the UPenn-GBM collection, and can be used for studies requiring the
skull, such as the evaluation of automatic brain extraction methods58. Furthermore, the defacing masks for each
subject were transferred back to the original space, consistent with the MRI acquisition and DICOM format data,
by applying the inverse transformation through the ‘Greedy’ tool52. These masks were then applied to the scans in
the original space, and the resultant de-faced images were written back to the DICOM format using CaPTk35,59,60
and made available in the UPenn-GBM collection. No defacing masks were applied to the DSC and the DTI scans
since facial information is not included in the originally acquired scans.
Brain extraction. Further to defacing all scans, we also extracted the brain using a routine process in neuroimaging called skull-stripping (also known as brain extraction). This process focuses on generating a brain
mask to remove all non-brain tissue from the image (including neck, fat, eyeballs, and skull), to enable further
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Fig. 3 Glioma sub-region labeling (A–D) and the overall tumor distribution atlas of the UPenn-GBM data
collection (E). Sub-figures A-D depict an example visual representation of the segmented glioma sub-regions
labels superimposed on different MRI scans. (A) the enhancing tumor (ET - yellow) superimposed on a T1-Gd
scan, surrounding the cystic/necrotic components of the tumor core; (B) the tumor core (TC–magenta)
superimposed on a T2 scan, highlighting the potentially resectable tumor; (C) the whole tumor (WT - cyan)
superimposed on a T2-FLAIR scan, showing all the abnormal tissue; (D) depicts the WT discretised in the
independent histologically-distinct tumor sub-region labels: enhancing tumor core (blue), necrotic/cystic core
(red), and peritumoral edematous/infiltrated tissue (green). (E) depicts the spatial distribution of the TC from
the complete set of the UPenn-GBM collection’s pre-operative scans.
computational analyses. Notably, for the brain extraction we used an in-house deep learning based approach,
namely the Brain Mask Generator (BrainMaGe)58 (https://github.com/CBICA/BrainMaGe), which has been
explicitly developed to address brain scans in presence of diffuse glioma, and takes into consideration the
brain shape as a prior, hence being agnostic to the sequence/modality input. Once the brain mask is generated, reviewed, and approved for a single sequence, it is then applied to all co-registered scans to obtain the
skull-stripped images included in the UPenn-GBM collection.

Tumor sub-region segmentation. Finally, the histologically distinct tumor sub-regions were segmented using a fully-automatic approach, based on the label fusion of a few deep learning algorithms that have
been top-ranked in the BraTS challenge15–18,33,50. Specifically, the segmentation labels of the enhancing tumor
(ET), the necrotic tumor core (NCR), and the peritumoral edematous/infiltrated tissue (ED) are considered.
Radiographically, the ET and NCR parts are defined by hyper-intense and hypo-intense areas, respectively, on
T1-Gd compared with T1, but also compared with normal-appearing white matter. The NCR regions describe
non-enhancing or faintly enhancing tumor core components, as well as transitional/pre-necrotic and necrotic
regions that belong to the non-enhancing part of the bulk tumor, and are typically surgically resected together
with the ET. Finally, the ED region is defined by the abnormal hyperintense signal envelope on the T2-FLAIR
volumes. A visual example of segmented tumor sub-regions can be found in Fig. 3.
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The patient’s co-registered and skull-stripped structural mpMRI (i.e., T1, T1-Gd, T2, T2-FLAIR) were used
as the input to each of the segmentation algorithms (i.e., DeepMedic61, DeepSCAN62, and nnUNet63) that partition the patient’s brain into the three aforementioned tumor sub-region labels, including a single label for
everything else. Subsequently, we applied the STAPLE label fusion technique64 to appropriately combine the
results of the three algorithms and overcome errors of individual methods. Furthermore, the tumor segmentation labels of a subset of 232 subjects were evaluated by S.M. and M.B. and manually refined when needed.

Perfusion and diffusion derivative volumes. We have used the acquired DTI volumes to extract commonly used derivative diffusion measurements that can be associated with the tissue microstructure and density65,
in the form of individual volumes, comprising the (i) tensor’s trace (DTI-TR), (ii) axial diffusivity (DTI-AD), (iii)
radial diffusivity (DTI-RD), and (iv) fractional anisotropy (DTI-FA). Furthermore, the DSC-MRI volumes were
used to extract parametric maps of isolated measurements summarizing the complete dynamic 4D perfusion
signal into a single 3D volume. These maps comprise the i) peak height (DSC-PH), ii) percentage signal recovery
(DSC-PSR), and an automated proxy to the relative cerebral blood volume (DSC-ap-rCBV)11,66–68. Note that both
the DTI and the DSC derivative maps can all be used as individual imaging volumes for further analyses. The
UPenn-GBM data also includes the DTI and DSC derivative volumes co-registered with the skull-stripped structural images to enable further computational studies.
Feature extraction. Following the definition of the distinct tumor sub-regions, all mpMRI sequences were

analyzed to extract relevant comprehensive quantitative imaging phenomic (QIP) features from each of the corresponding sub-regions. Such features have been extensively used for the development of predictive models for
diagnostic, planning, and prognostic purposes, as well as to characterize CNS tumors comprehensively, and provide critical information about various biological processes within the tumor microenvironment, as well as associations with underlying cancer molecular characteristics11,12,14,39,68–107.
We have specifically extracted 145 features for each annotated sub-region and from each MRI sequence separately using the Cancer Imaging Phenomics Toolkit (CaPTk, www.cbica.upenn.edu/captk)35,59,60,108,109, which
has been extensively used in radiomic analysis studies16,58,69,97,109. The exact features extracted from CaPTk, in
compliance with the Image Biomarker Standardisation Initiative (IBSI)34,110, include five primary feature groups:
i) intensity-based features, ii) histogram-related, and iii) volumetric measurements, iv) morphological parameters, and v) textural descriptors. The intensity-based features include first-order statistics (e.g., mean, median,
maximum, minimum, standard deviation, skewness, kurtosis) capturing information of the overall intensity
distribution profile within each sub-region within a given image/scan. Additional characteristics are provided
by histogram-related measures, which describe the range and distribution of image grey-level intensity levels. Volumetric parameters capture shape information in morphologic metrics such as elongation, perimeter,
principal component axes, and area or volume for two- or three-dimensional data, respectively. Last, textural
descriptors include a wide range of indices describing the local variation and spatial dependence of image intensities (based on grey-level co-occurrence (GLCM)111, grey-level run-length (GLRLM)112–116, gray-level-size zone
(GLSZM)113–115,117, and neighborhood gray-tone difference (NGTDM) matrices)118, as well as local binary patterns119, which characterize intrinsic periodic texture structures that repeat over multiple image scales.
CaPTk ships with a default parameter file for feature calculations, which, however, can be customized by
the user based both on image protocol specifications (e.g., slice thickness, pixel/voxel resolution, image reconstruction filters), but also allows for further optimization of these parameters based on feature associations with
specific endpoints of interest, such as molecular markers, clinical outcomes, treatment responses, and other
patient outcomes, to further boost feature performance. CaPTk’s default parameterization values were the ones
we considered to obtain the features that we are providing. We provide these extracted radiomic features on an
‘as-is’ basis, while making no claim for their superiority or their biological significance. These are included here
to facilitate research on their association with molecular markers, clinical outcomes, treatment responses, and
other endpoints, by researchers without sufficient computational background to extract such features. The list of
the radiomic features extracted, as well as the specific parameterization file for extracting them through CaPTk,
are made available and can downloaded from the TCIA repository37.

Data Records

All the data described here as the “UPenn-GBM” collection37, are available from the publicly available repository
of The Cancer Imaging Archive (TCIA)31 at: https://doi.org/10.7937/TCIA.709X-DN49. Data availability per
subject can also be found and downloaded from the TCIA repository37.

Technical Validation

Clinical data & molecular characterizations.

All clinical and molecular characteristics of the subjects
included in the “UPenn-GBM” collection were obtained retrospectively from clinical records (e.g., radiology &
pathology reports), that were used for patient management. No additional validation of these raw clinical data
was conducted as part of the “UPenn-GBM” release.

Image processing steps. All the image processing related steps were manually reviewed, and either
approved, or corrected as deemed necessary. However, it is important to note that there was a high level of uncertainty reported by radiologists, radiation oncologists, surgeons, and imaging scientists as to the exact boundaries between the various tissues assessed, most notably in the tumor labels, where visual assessment is always
ambiguous.
Image pre-processing. The image pre-processing pipeline included a manual assessment for sufficient quality
at various steps, as indicated in Fig. 2. Specifically, after the registration of all mpMRI volumes to the common
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anatomical atlas, all scans were manually reviewed for misalignment and corrected through ITK-SNAP120,121
when necessary.
Image de-facing. The derived defacing masks for all cases were visually checked for quality, and approximately
10% of them were manually refined as needed.
Brain extraction & tumor segmentation. The automatically derived brain masks and tumor segmentation labels
for all the included cases were visually checked for quality and manually refined as needed, prior to proceeding
with further analysis. Manual refinements that were applied in the computer-aided segmentation labels comprise: i) obvious under- or over-segmentation of regions (brain/ET/NCR/ED), ii) voxels classified as ED within
the tumor core, iii) unclassified voxels (i.e., holes) within the tumor core, iv) voxels classified as NCR outside
the tumor core. Note that in line with the protocol followed by BraTS, during the manual corrections only peritumoral ED was considered, and contralateral, as well as any periventricular ED was removed, unless it was a
contiguous area with the peritumoral ED. The rationale for this is that contralateral and periventricular white
matter hyper-intensities might be considered pre-existing conditions, and/or related to small vessel ischemic
disease, especially in older patients.

Perfusion derivatives.

The DSC scans are obtained by preloading half of the total contrast agent to reduce
the effect of contrast agent leakage, followed by the second half of the total contrast volume. The raw signal time
curve was inspected to confirm proper bolus administration, as the data must have sufficient time before and after
the signal drop to calculate the derivative images including PH, PSR, and ap-RCBV11,66–68. Any images that did
not meet these criteria were excluded from further analysis.

Diffusion derivatives. Diffusion tensor derivatives were manually inspected for coverage of the entire brain

and their co-registration to the structural MRI scans. Fractional anisotropy values were required to be real values
between 0 and 1. Unweighted (b = 0) images were required to be positive, due to numerical problems that arise
when fitting a tensor in a voxel with an unweighted value of 0. Any voxels that did not meet these requirements
were excluded from further analysis.

Feature extraction. Considering the mathematical formulation of these features, it is possible for a division
by zero to occur (lack of heterogeneity or very small number of voxels). In CaPTk, we return “not a number” as
the result of these features to enable the user to make subsequent downstream analyses more coherent based on
the entire population. We acknowledge this could be provided as “inf ” instead, but we are providing this as “NaN”
to have parity between various programming languages and processing protocols.

Usage Notes

Potential use cases of the hereby presented UPenn-GBM data collection could be influenced by and aligned with
previous findings utilizing subsets of the data collection. Specifically, cases that have been included in previously
example published studies, comprise 63 cases used in a study to predict the location of tumor recurrence from
pre-operative baseline MRI scans95, 120 cases used in a study predicting the molecular subtype of glioblastoma
and performing an imaging-based patient prognostic stratification97, 98 cases used in a study predicting patient
overall survival utilizing only routine structural MRI scans69, 173 cases used in the International Brain Tumor
Segmentation (BraTS) challenge18, and in the Federated Tumor Segmentation (FeTS) challenge122, 60 cases used
in a study distinguishing true progressive disease from pseudoprogression39, 250 cases used in a study identifying imaging subtypes offering prognostic value beyond IDH99, and 86 cases used in a study designing a brain
extraction method explicitly designed for brain glioma MRI scans58.

Code availability

In line with the scientific data principles of Findability, Accessibility, Interoperability, and Reusability (FAIR)123,
the tools used throughout the generation of these data are publicly available. Specifically, we have used the Insight
Toolkit (ITK)124 to convert the raw DICOM files to the NIfTI file format49, and when this mechanism did not
work we have used the dcm2niix software (version 1.0.20200331)125. All image registrations were performed
using the ‘Greedy’ registration algorithm (https://github.com/pyushkevich/greedy)52, a CPU-based C++
implementation of the greedy diffeomorphic registration algorithm53. ‘Greedy’ is integrated into the ITK-SNAP
segmentation software120,121 (https://www.itksnap.org/, version: 3.8.0, last accessed: 27/May/2020), as well as into
the Cancer Imaging Phenomics Toolkit (CaPTk)35,59,60 (www.cbica.upenn.edu/captk, version: 1.8.1, last accessed:
11/February/2021). For the defacing of the acquired scans we used the “mri_deface” tool (https://surfer.nmr.
mgh.harvard.edu/fswiki/mri_deface), and for the brain extraction we used BrainMaGe version 1.0.458 (https://
github.com/CBICA/BrainMaGe). In addition, the CaPTk platform35,59,60,108,109, version 1.8.1, was used for all the
preprocessing steps, as well as for obtaining the perfusion derivatives, and generating the output DICOM files
(https://cbica.github.io/CaPTk/ht_utilities.html) after defacing of the data. The implementation producing the
diffusion derivatives will be available in CaPTk v.1.9.0. CaPTk’s source code and binary executables are publicly
available for multiple operating systems through its official GitHub repository (https://github.com/CBICA/CaPTk).
The implementation and configuration of the pre-trained segmentation models used in this study can be found
in the GitHub page of the Federated Tumor Segmentation (FeTS) platform (https://github.com/CBICA/FeTS).
Finally, ITK-SNAP120,121 version 3.8.0 was used for all manual annotation refinements.
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